Edition:
United Kingdom

OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

3.02USD
26 Apr 2018
Change (% chg)

$0.10 (+3.60%)
Prev Close
$2.91
Open
$2.94
Day's High
$3.11
Day's Low
$2.89
Volume
27,738
Avg. Vol
58,785
52-wk High
$5.55
52-wk Low
$1.75

Chart for

About

OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. The Company's therapeutic candidates and preclinical programs include... (more)

Overall

Beta: 2.74
Market Cap(Mil.): $164.07
Shares Outstanding(Mil.): 37.63
Dividend: --
Yield (%): --

Financials

  OMED.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -2.38 -- --
ROI: -75.79 1.58 14.38
ROE: -- 2.41 16.07

BRIEF-OncoMed Announces Appointment Of John Lewicki As CEO

* ONCOMED ANNOUNCES APPOINTMENT OF JOHN LEWICKI, PHD, AS PRESIDENT, CHIEF EXECUTIVE OFFICER AND A MEMBER OF THE BOARD OF DIRECTORS

19 Mar 2018

BRIEF-Oncomed Pharmaceuticals Reports Q4 Earnings Per Share $0.25

* ONCOMED PHARMACEUTICALS - CURRENT CASH IS ESTIMATED TO BE SUFFICIENT TO FUND OPERATIONS THROUGH AT LEAST Q3 OF 2019

08 Mar 2018

BRIEF-OncoMed Q4 Earnings Per Share $0.25

* ONCOMED ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

08 Mar 2018

BRIEF-Oncomed Says Chief Executive Officer Paul Hastings Has Resigned

* ONCOMED ANNOUNCES CHAIRMAN, PRESIDENT AND CHIEF EXECUTIVE OFFICER PAUL J. HASTINGS HAS RESIGNED

04 Jan 2018

BRIEF-OncoMed Estimates 2018 Operating Cash Burn To Be Less Than $55 Mln

* ONCOMED PROVIDES 2018 OUTLOOK AND 2017 YEAR-END CASH BALANCE AND ANNOUNCES AN UPDATE ON THE ROSMANTUZUMAB PROGRAM

04 Jan 2018

BRIEF-Perceptive Advisors reports 6.5 pct passive stake in Oncomed Pharmaceuticals

* PERCEPTIVE ADVISORS LLC REPORTS A 6.5 PCT PASSIVE STAKE IN ONCOMED PHARMACEUTICALS INC AS OF NOV 6 - SEC FILING Source text: [http://bit.ly/2nzZrC0] Further company coverage:

06 Dec 2017

BRIEF-Oncomed says CEO Paul Hastings to Resume Chairman of Board Responsibilities

* ONCOMED - ‍CHAIRMAN, PRESIDENT, CEO PAUL HASTINGS WILL RESUME CHAIRMAN OF BOARD RESPONSIBILITIES, EFFECTIVE DEC. 4, 2017​

27 Nov 2017

BRIEF-Oncomed posts Q3 loss per share $0.28

* Oncomed announces third quarter 2017 financial results and operational highlights

02 Nov 2017

Competitors

Earnings vs. Estimates